velafermin

Velafermin is a recombinant human protein therapeutic, also known as fibroblast growth factor 20 (FGF-20). It was developed as an investigational agent to promote epithelial and mesenchymal cell proliferation, with demonstrated activity in multiple animal models. Velafermin acts by stimulating DNA synthesis and cell proliferation through activation of fibroblast growth factor receptor (FGFR). Its primary indication was the prevention and treatment of oral mucositis, particularly in patients undergoing high-dose chemotherapy or autologous stem cell transplantation. The drug was investigated in Phase II clinical trials but did not meet its primary efficacy endpoint for oral mucositis prevention[1][2][3][4][5].

Other names

fibroblast growth factor 20recombinant human fibroblast growth factor 20FGF-20FGF20FGF 20FIBROBLAST GROWTH FACTOR 20 (HUMAN RECOMBINANT CG53135)